نتایج جستجو برای: braf mutation

تعداد نتایج: 295289  

Journal: :Anticancer research 2007
Hirotaka Nakayama Akira Yoshida Yoshiyasu Nakamura Hiroyuki Hayashi Youhei Miyagi Nobuyuki Wada Yasushi Rino Munetaka Masuda Toshio Imada

BACKGROUND Activating mutations of the BRAF gene have recently been reported in thyroid carcinomas. In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma (PTC). PATIENTS AND METHODS In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extr...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Ademi Santiago-Walker Robert Gagnon Jolly Mazumdar Michelle Casey Georgina V Long Dirk Schadendorf Keith Flaherty Richard Kefford Axel Hauschild Patrick Hwu Patricia Haney Anne O'Hagan Jennifer Carver Vicki Goodman Jeffrey Legos Anne-Marie Martin

PURPOSE Tumor-derived circulating cell-free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) trametinib were analyzed to determine the association between BRAF mutation status in cfDNA and tumor tissue, and the association of BRAF cfDNA mutation sta...

Journal: :International journal of clinical and experimental medicine 2003
Xinying Li Asim B Abdel-Mageed Emad Kandil

BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC). Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of the BRAF muta...

2017
Yan Xu Rui Bi Yaoxing Xiao Xiaoyu Tu Ming Li Anqi Li Ling Shan Shuling Zhou Wentao Yang

BACKGROUND Mounting evidence has shown that KRAS and BRAF are somatic mutations associated with low grade serous carcinoma (LGSC) of the ovary. However, the frequency of KRAS or BRAF mutation was variable in literatures, with a frequency of 16-54% for KRAS mutation and 2-33% for BRAF mutation. Meanwhile, the prognostic significance of KRAS or BRAF mutation remains controversial. METHODS Codon...

2013
Yong-Seok Kim Jeong-Soo Kim Ja-Seong Bae Woo-Chan Park

Background: The BRAF mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). In recent studies, the BRAF mutation has been associated with poor clinicopathological characteristics, such as lymph node metastasis, extrathyroidal extension, and advanced stage. However, other studies have failed to establish an association between the BRAF mutation and clinicopathologic...

شکوری گرکانی, عباس, ظریفیان یگانه, راضیه, عبادی, نادر, مطیعی لنگرودی, مازیار, مهرابی, سامان, نوری دلویی, محمدرضا,

Background: Head and neck squamous cell carcinoma (HNSCC) is the malignancy of squamous cells (the epidermal layer of skin) in cavities in head and neck includes: larynx, pharynx, paranasal sinuses and oral cavity. The main goal of this research was to understand the effect of mutations in two important genes (KRAS and BRAF) in RAS/MAP kinase (EGFR) signaling pathway in tumor cells with head an...

2014
Jin-Woo Hong Suee Lee Dae-Cheol Kim Ki-Ho Kim Ki-Hoon Song

BACKGROUND In the majority of melanomas, the RAS/RAF/MEK/ERK signaling pathway is constitutively activated, due to oncogenic mutations in the BRAF and NRAS genes. The BRAF mutation has been mainly described in Caucasian melanomas. However, there is a lack of study evaluating the status, and the clinical significance, of BRAF mutation in the Asian population. OBJECTIVE This study was aimed to ...

2017
Anna Caliò John N. Eble Ondrej Hes Guido Martignoni Saul E. Harari Sean R. Williamson Matteo Brunelli Adeboye O. Osunkoya Lisha Wang Eva Comperat Antonio Lopez-Beltran Mingsheng Wang Shaobo Zhang Kendra L. Curless Kristin M. Post Hsim-Yee Chang Claudio Luchini Lee Ann Baldrige Gregory T. MacLennan Rodolfo Montironi David J. Grignon Liang Cheng

BRAF mutation recently has been reported in metanephric adenoma. We sought to determine the clinical and morphologic features of BRAF-mutated metanephric adenoma and to correlate BRAF mutation with BRAF V600E immunohistochemical staining results. A series of 48 metanephric adenomas and 15 epithelial-predominant nephroblastomas were analyzed for the occurrence of BRAF mutation (BRAF V600E/V600E ...

Journal: :Journal of the National Cancer Institute 2009
Jingrong Lin Minoru Takata Hiroshi Murata Yasufumi Goto Kenji Kido Soldano Ferrone Toshiaki Saida

Melanocytic nevi are thought to be senescent clones of melanocytes that have acquired an oncogenic BRAF mutation. BRAF mutation is considered to be a crucial step in the initiation of melanocyte transformation. However, using immunomagnetic separation or laser-capture microdissection, we examined BRAF mutations in sets of approximately 50 single cells isolated from acquired melanocytic nevi fro...

Journal: :Genetics and molecular research : GMR 2015
R C da Silva H S C de Paula C B Q S Leal B C R Cunha E C de Paula R C G Alencar A J Meneghini A M T C Silva A P Gontijo I J Wastowski V A Saddi

A common mutation in the BRAF gene, comprising the T1799A nucleotide transversion, which leads to the V600E amino acid substitution in the BRAF protein, has been observed in about 50% of papillary thyroid carcinomas (PTCs). However, BRAF protein expression has been rarely examined in such tumors. Clinical studies have shown important associations between BRAF mutation and clinical parameters in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید